The dopamine transporter's lipid interactions: understanding transporter function

多巴胺转运蛋白的脂质相互作用：了解转运蛋白的功能

• 批准号: 10317085
• 负责人: AURELIO GALLI
• 金额: $ 42.27万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10317085
• 关键词: Action Potentials; American; Amphetamines; Animal Model; Attention Deficit Disorder; Attention deficit hyperactivity disorder; Award; Behavior; Behavioral; Behavioral Assay; Biochemical; Biochemistry; Biological Assay; Biological Models; Biophysics; Brain; Cell membrane; Cells; Cessation of life; Charge; Complex; Computer Models; Data; Distal; Dopamine; Drosophila genus; Drosophila melanogaster; Electrophysiology (science); Electrostatics; Elements; Event; Family member; Human; Impairment; Lipids; Locomotion; Measures; Mediating; Medical; Membrane; Membrane Lipids; Membrane Proteins; Modification; Molecular; Molecular Conformation; Motor; Movement; Mutation; N-terminal; Neurons; Outcome; Pharmaceutical Preparations; Pharmacology; Phosphatidylinositol 4,5-Diphosphate; Phosphatidylinositols; Phosphorylation; Play; Probability; Process; Property; Reporting; Rewards; Role; Stimulant; System; Testing; Translating; United States National Institutes of Health; United States Substance Abuse and Mental Health Services Administration; abuse liability; base; behavioral phenotyping; behavioral study; biological preparation; dopamine transporter; dopaminergic neuron; extracellular; fly; in vivo; lipid I; molecular dynamics; neuropsychiatric disorder; preference; psychostimulant; uptake

Amphetamines (AMPHs) are psychostimulants commonly used for the treatment of neuropsychiatric disorders (e.g. attention deficit disorders). They are also abused, with devastating outcomes. The abuse potential of AMPHs has been associated with their ability to cause mobilization of cytoplasmic dopamine (DA), which leads to an increase in extracellular DA levels. This increase is mediated by the reversal of the DA transporter (DAT) function that causes non-vesicular DA release, herein defined as DA efflux. However, the molecular events underlying DA efflux and how these events translate to specific AMPH behaviors is not well understood and is the focus of this proposal. We have shown that the DAT N-terminus (NT) is a structural domain that upon phosphorylation supports AMPH-induced DA efflux, but does not regulate DA uptake. Also, our preliminary data indicate that this phosphorylation event regulates DA-associated behaviors. Previously, using a combination of biochemistry, electrophysiology, and atomistic molecular dynamics simulations, as well as behavioral assays, we have shown that the DAT NT contains structural elements (Lys) that interact with plasma membrane lipids, specifically, phosphatidylinositol (4,5)-bisphosphate (PIP2). Impairing the interaction of the DAT NT with PIP2, either pharmacologically or molecularly, inhibits both DA efflux and AMPH hyperlocomotion. This was the first demonstration that the interaction of a plasma membrane protein with PIP2 is essential for psychostimulant behaviors. It also raised the possibility, that this interaction is essential for AMPH to cause DAT NT phosphorylation. DA efflux also requires the NT to be present and highly dynamic, since either anchoring the DAT NT to the plasma membrane or deleting the NT impairs DA efflux, but not DA uptake. Our mechanistic hypothesis is that the interaction between the NT and PIP2 is pivotal for AMPH to cause NT phosphorylation. Upon phosphorylation, the DAT NT uncouples from PIP2 and disengages from the membrane, forming new interactions with a specific motif of intracellular loop 4 (IL4) as predicted by our preliminary data. These new interactions, facilitated by NT phosphorylation, are essential for AMPH actions. We propose to test this hypothesis through the following specific aims: 1) To determine the role of hDAT-plasma membrane interactions in regulating NT phosphorylation; 2) To determine how hDAT NT phosphorylation supports DA efflux and the involvement of IL4. Our molecular discoveries will be then translated in vivo using Drosophila melanogaster as an animal model in which we express the human DAT (hDAT) in DA neurons of flies lacking the Drosophila DAT (“humanized flies”). In this animal model, we developed the ability to study hDAT function in isolated brains, both biochemically and biophysically, and to determine whether molecular manipulations of hDAT impairing DA efflux, but not uptake, impair complex behaviors associated with AMPH, including reward/preference. Therefore, in specific aim 3) we will determine the requirement of hDAT IL4-PIP2 interactions for AMPH-induced behaviors and the role played by NT phosphorylation.

安非他明（AMPHs）是一种精神兴奋剂，通常用于治疗神经精神疾病（如注意力缺陷障碍）。他们也被虐待，带来毁灭性的后果。AMPHs的滥用潜力与它们引起细胞质多巴胺（DA）动员的能力有关，这导致细胞外DA水平增加。这种增加是由DA转运蛋白（DAT）功能的逆转介导的，该功能导致非囊性DA释放，此处定义为DA外排。然而，DA外排背后的分子事件以及这些事件如何转化为特定的AMPH行为尚未得到很好的理解，这是本提案的重点。我们已经证明，DAT n端（NT）是一个结构域，在磷酸化后支持amph诱导的DA外排，但不调节DA摄取。此外，我们的初步数据表明，该磷酸化事件调节da相关行为。先前，通过结合生物化学、电生理学、原子分子动力学模拟以及行为分析，我们已经证明DAT NT含有与质膜脂相互作用的结构元件（Lys），特别是磷脂酰肌醇(4,5)-二磷酸（PIP2）。损害